Spexis to host business update conference call on October 9, 2023

Spexis AG / Key word(s): Statement Spexis to host business update conference call on October 9, 2023 06.10.2023 / 07:30 CET/CEST     Spexis to host business update conference call on October 9, 2023   Allschwil, Switzerland, October 6, 2023   Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT. Jeffrey D. Wager, M.D. (CEO & Chairman) will provide strategic business and financial updates. To access the conference call please use the following details: France: [phone] Germany: [phone] Italy: [phone] Switzerland [phone] United Kingdom [phone] United States [phone] International Toll Free [phone]   Event Title: Spexis AG – Business Update Conference Call   The conference call will also be available via webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=6s6eCE7g After the call, a replay of the webcast will be available via the above link.   About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com.   For further information please contact: For Investors:    Hernan Levett Chief Financial Officer Spexis AG. [phone] [e-mail] Or Stephen Jasper Managing Director Gilmartin Group [e-mail]   For Media:    Dr. Stephan Feldhaus Feldhaus & Partner [phone] [e-mail]     End of Media Release

Language:	English
Company:	Spexis AG
	Hegenheimermattweg 125
	4123 Allschwil
	Switzerland
Phone:	[phone]
Fax:	[phone]
E-mail:	[e-mail]
Internet:	www.spexisbio.com
ISIN:	CH0106213793
Valor:	SPEX
Listed:	SIX Swiss Exchange
EQS News ID:	1742821

End of News	EQS News Service

1742821  06.10.2023 CET/CEST